HomeFUNDING
FUNDING
Medical device and diagnostics companies are always looking for ways to improve their products and services. In the ever-changing landscape of the healthcare industry, it’s essential for these companies to stay ahead of the curve. That’s why funding is always news.
Series A, B, and other rounds of funding are essential for medical device and diagnostics companies. They provide the necessary capital to help these businesses grow and innovate. And with so many investors interested in this space, there are plenty of opportunities for companies to secure the funding they need.
RetiSpec Closes $10M USD to Advance Commercialization of its AI-Driven Eye Test for Detection of Alzheimer’s Disease
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.
Pearl Raises Largest-Ever Investment in Dental AI with $58 Million Round
The landmark investment in dental artificial intelligence enables Pearl to further expand its dental AI solutions and meaningfully improve oral health outcomes for patients.
Samsung Ventures Among Top Investors Backing AI Imaging Acquisition Market Leader Subtle Medical – Bringing Total Series B to Over $30 Million
The funds will primarily support accelerating US and global sales initiatives and expediting the launch of new AI-driven products notes Subtle Medical.
Novo Holdings Leads $105 Mil Financing of Magenta Medical | To Support FDA Approval for World’s Smallest Heart Pump
Novo Holdings reports the funds will be used to advance Magenta’s US clinical programs to support the FDA’s approval of the Elevate™ System, the world’s smallest heart pump.
Ora Announces Strategic Investment from The Vistria Group to Propel Global Growth, Enhance Customer Experience in Ophthalmic Research
With this investment, The Vistria Group will support Ora as the globally preferred clinical research partner of ophthalmic innovators. It also marks The Vistria Group’s commitment to further supporting cutting-edge therapies and advancing diversity in specialized clinical research. Ora is the seventh company in The Vistria Group’s pharma services portfolio and underscores the firm’s continued focus on life sciences.
Hanger Ventures Announces Inaugural Investment
“We are thrilled to make our inaugural investment in Bionic Power,” shared James Campbell, Ph.D., Hanger Ventures President and Hanger, Inc. Chief Clinical Officer. “We look forward to contributing clinical research, along with technical and commercial expertise, to bring innovative solutions to the market that have the potential to meet an unmet clinical need and improve the quality of life for individuals with mobility challenges.”
Novocuff Raises $26 Million in Oversubscribed Series A Funding to Advance Technology Aimed at Reducing Preterm Births
“We are thrilled to have the support of a strong and mission-aligned group of investors as we enter this exciting next phase of clinical development,” said Amelia “Amy” Degenkolb, CEO & Co-founder of Novocuff. “This funding catalyzes our ability to deliver a solution to a healthcare need for women, and their families and healthcare providers.”
Digestiva Closes $18.4 million Series A Financing
Digestiva reports this significant milestone was led by Magdalena, a global leader in sugar cane processing, with participation from UC Investments, and existing investors The March Fund and Astanor. The company's groundbreaking enzyme technology platform was initially discovered by co-founder Dr. Wilson Mak, in the lab of renowned UC Davis faculty member Dr. Justin Siegel, a global leader in enzyme discovery, development, and design.
Neuspera Medical Raises $23 Million in Series D Financing
Neuspera Medical notes this round will fund the company though expected U.S. Food and Drug Association (FDA) premarket approval (PMA) of the Neuspera System, the discreet, minimally invasive, ultra-miniaturized implant designed to provide patients personal control and relief from urinary urge incontinence (UUI), a symptom of overactive bladder (OAB).
Spotlight Medical Secures €6.2M in Seed Funding to Enhance Cancer Treatment Strategies with AI-Powered Prognosis Tests
This funding will enable Spotlight Medical to bring its first prognosis test to the clinic, marking a significant milestone in the commercialization of AI-based solutions for cancer treatment. By leveraging decades of patient treatment data, Spotlight Medical aims to ensure that no patient is over or undertreated, ultimately improving cancer outcomes.
Recent News
MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES
Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants
"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."
MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES
Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting
This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.
MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES
Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution
“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”